Free Trial

QTR Family Wealth LLC Acquires Shares of 4,238 Tempus AI, Inc. $TEM

Tempus AI logo with Medical background

Key Points

  • QTR Family Wealth LLC acquired 4,238 shares of Tempus AI, Inc., representing a new stake worth approximately $269,000 during the 2nd quarter.
  • Insider transactions include CEO Eric P. Lefkofsky selling 332,500 shares for over $25 million, marking a 3.51% decrease in his ownership.
  • Tempus AI's stock is currently priced at $80.71, with analysts setting an average target price of $71.83, reflecting a general sentiment of a "Moderate Buy."
  • Five stocks to consider instead of Tempus AI.

QTR Family Wealth LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,238 shares of the company's stock, valued at approximately $269,000.

Several other institutional investors have also recently made changes to their positions in TEM. First Horizon Advisors Inc. grew its position in Tempus AI by 12.7% during the 1st quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company's stock worth $89,000 after purchasing an additional 208 shares during the period. Farther Finance Advisors LLC grew its holdings in Tempus AI by 59.9% during the second quarter. Farther Finance Advisors LLC now owns 884 shares of the company's stock worth $56,000 after acquiring an additional 331 shares during the period. Bartlett & CO. Wealth Management LLC raised its position in Tempus AI by 100.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock valued at $39,000 after acquiring an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tempus AI by 10.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,594 shares of the company's stock valued at $268,000 after acquiring an additional 515 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Tempus AI by 6.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,681 shares of the company's stock valued at $590,000 after acquiring an additional 560 shares during the period. Hedge funds and other institutional investors own 24.22% of the company's stock.

Insider Activity at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of the stock in a transaction that occurred on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total value of $25,456,200.00. Following the completion of the sale, the chief executive officer owned 9,141,032 shares of the company's stock, valued at approximately $699,837,409.92. This trade represents a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Erik Phelps sold 3,664 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $273,517.60. Following the transaction, the executive vice president owned 94,115 shares in the company, valued at approximately $7,025,684.75. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 933,662 shares of company stock worth $67,909,393 in the last 90 days. 26.27% of the stock is owned by insiders.

Tempus AI Stock Up 2.7%

Shares of TEM opened at $80.71 on Wednesday. The stock has a 50 day moving average price of $73.46 and a 200 day moving average price of $62.41. Tempus AI, Inc. has a one year low of $31.36 and a one year high of $97.79. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. The stock has a market capitalization of $14.02 billion, a price-to-earnings ratio of -67.82 and a beta of 5.08.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million for the quarter, compared to analysts' expectations of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm's quarterly revenue was up 89.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TEM shares. Morgan Stanley lifted their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Guggenheim lifted their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a report on Friday, September 26th. HC Wainwright lifted their price target on Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Bank of America upped their price target on Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, June 25th. Finally, Piper Sandler reissued a "neutral" rating on shares of Tempus AI in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Tempus AI presently has an average rating of "Moderate Buy" and an average target price of $71.83.

Read Our Latest Analysis on TEM

Tempus AI Profile

(Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Featured Stories

Institutional Ownership by Quarter for Tempus AI (NASDAQ:TEM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Options Myths Costing You Money (Do This Instead)
The Best & Worst Stocks in the Market Right Now
October Slowdown? 5 Signs to Watch Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines